AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

AbbVie Inc.NYSE: ABBV

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares dips below year-ago levels

Q3 FY2026 weighted avg shares of 1.77B shares fell 0.0% year over year, in line with the +0.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -0.0% toward the trailing-twelve-month pace of +0.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
1.77B+0.1% QoQ
Last fiscal yearDec 2025
1.77B+0.3% YoY
LTMSep 2026
1.77B+0.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.0%——
1 year+0.3%——
3-year CAGR+0.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
1.77B USD
Year-over-year change
+0.3%
4-year CAGR
+0.1%

Weighted Avg Shares vs competitors

How ABBV compares with its peers on the latest reported figures

  • ABBV's LTM Sep 2026 weighted avg shares of 1.77B shares is the 7th highest of the 10 companies compared; the peer median is 2.01B shares.
  • Its year-over-year change of +0.1% is the 5th highest of 10, against a peer median of -0.2%.
  • Over three fiscal years its annual growth of +0.1% compares with a peer median of -0.4%.
ABBV Competitors Peer median
Weighted Avg Shares for ABBV and competitors
Company Period LTM YoY 3-year CAGR
PFEPfizer Inc.LTM Jun 20265.69B +0.3%+0.4%
MRKMerck & Co., Inc.LTM Jun 20262.48B -2.0%-0.4%
JNJJohnson & JohnsonLTM Sep 20262.44B +1.0%-2.4%
BMYBristol-Myers Squibb CompanyLTM Jun 20262.04B +0.5%-1.4%
GSKGSK plcLTM Jun 20262.01B -1.4%+0.2%
NVSNovartis AGLTM Jun 20261.91B -3.3%-3.8%
ABBVAbbVie Inc.LTM Sep 20261.77B +0.1%+0.1%
AZNAstraZeneca PLCLTM Sep 20261.55B -0.2%+0.0%
LLYEli Lilly and CompanyLTM Jun 2026895.45M -0.4%-1.9%
AMGNAmgen Inc.LTM Jun 2026539.25M +0.2%+0.0%
Peer median (excluding ABBV) 2.01B-0.2%-0.4%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.2B58.05B54.32B56.33B61.16B
Cost of Revenue17.45B17.41B20.42B16.9B18.2B
Gross Profit38.75B40.64B33.9B39.43B42.96B
Gross Margin69.0%70.0%62.4%70.0%70.2%
Research & Development8.05B6.51B7.68B12.79B9.1B
Selling, General & Admin12.35B15.26B12.87B14.75B14.01B
Operating Expenses20.83B22.52B21.15B30.29B22.87B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
EBITDA23.93B24.17B17.17B14.91B17.63B
EBITDA Margin42.6%41.6%31.6%26.5%28.8%
Operating Income17.92B18.12B12.76B9.14B20.09B
Operating Margin31.9%31.2%23.5%16.2%32.8%
Interest Income39M186M540M648M266M
Interest Expense2.42B2.23B2.22B2.81B2.89B
Other Income / Expenses(4.94B)(4.64B)(6.51B)(5.42B)(13.49B)
Income Before Tax12.99B13.48B6.25B3.72B6.6B
Pre-Tax Margin23.1%23.2%11.5%6.6%10.8%
Income Tax Expense1.44B1.63B1.38B(570M)2.36B
Net Income11.54B11.84B4.86B4.28B4.23B
Net Margin20.5%20.4%9.0%7.6%6.9%
EPS (Basic)6.486.652.732.402.37
EPS (Diluted)6.456.632.722.392.37
Weighted Avg Shares1.77B1.77B1.77B1.77B1.77B
Weighted Avg Shares (Diluted)1.78B1.78B1.77B1.77B1.77B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.